Finding Ways to Finance the Growing Costs of Clinical Trials
Over the past few months the majority of the news coming out of the pharmaceutical industry has been a refrain of slashing R&D spending as a result of increasingly competitive drug development.
Over the past few months the majority of the news coming out of the pharmaceutical industry has been a refrain of
Still,
One clear advantage of this new concept is minimizing risk exposure for the company. According to the Financial Times, several other companies have similar plans in the works. Trying to share the financial burden of clinical trials has become the norm for many companies, including disease-specific partnerships and negotiated milestones with CROs for payments.
As the era of the blockbuster drug winds down, companies are understandably wary of putting large amounts of money into risky ventures for products that have a limited potential patient population. The patent cliff hasn’t been as apocalyptic as some may have feared, but the dent in revenues has been impossible to ignore. Companies are trying to answer the question of how to produce better, more targeted drugs with less money than they’ve had in the past.
A more macro approach to this problem has been taken by Eli Lilly, which has been able to
Jacob Presson is a research analyst at Cutting Edge Information, providing market research to pharmaceutical companies.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025